AAIPharma, Inc. Selects Phase Forward for its Global Leadership and Flexible Partner Program
A rapidly growing, full-service global CRO with operations throughout the United States, Canada, Western and Eastern Europe and South America, AAIPharma selected the InForm system and the Clintrial product after completing a rigorous industry product review. The company decided on Phase Forward for its global reach and stability, and industry-proven product offerings, as well as its innovative approach to CRO partnership. In addition, AAIPharma was drawn to the products' straightforward implementation requirements and intuitive interface, requiring very little training post-deployment.
"After an intense review process we felt Phase Forward's dedicated services organization, combined with its trusted product set, made our decision an easy one," said Anne Wiles, senior vice president, Data Systems and Processes, AAIPharma. "The company's flexible partner program will allow us to expand and customize our offerings at a pace that best suits our growing organization, as well as our clients. As EDC adoption continues, it is important that we offer the technology that sponsors view as an industry standard, while also supporting those clients requiring a solution that supports both electronic and paper-based trials. Phase Forward remains the vendor of choice for organizations at every stage of EDC implementation."
"CROs continue to play a critical role in bringing the efficiencies of electronic data capture and management to clinical trials, and will ultimately help move the industry further along the adoption continuum over the next several years," said Bob Weiler, CEO and president, Phase Forward. "Collaboratively, we believe we can help biopharmaceutical and medical device firms realize the full benefits of EDC, and we look forward to working with AAIPharma in pursuing this goal."
About AAIPharma
AAIPharma Inc. is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. From a single test through a range of integrated service offerings, we create value to an industry in search of productivity and innovation. For more information, please visit www.aaipharma.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm(TM)), clinical data management (Clintrial(TM)), clinical trials signal detection (CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal Management), adverse event reporting (Clintrace(TM)) and applied data standards (WebSDM(TM)). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 250 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward's products and services, future business and operations plans of Phase Forward customers and alliance partners, and the ability of Phase Forward's customers and alliance partners to realize benefits from the use of Phase Forward's products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers and alliance partners to realize benefits from the use of its products and services, changes in regulatory requirements applicable to Phase Forward's customers and alliance partners, the manner in which Phase Forward's customers and alliance partners conduct business and the possibility that their needs or plans may change over time, and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Quarterly Report on Form 10-Q.
Contact:
Phase Forward Gretchen Dock, 781-902-4413 gretchen.dock@phaseforward.com or
CHEN PR, Inc. Juli Greenwood, 781-672-3137 jgreenwood@chenpr.com
Source: Phase Forward